The Westin Casuarina
160 East Flamingo Rd.
Las Vegas, Nevada 89109
Tel.: +1 (702) 836 9775
Fax: +1 (702) 836 9776

Las Vegas, Nevada

Chairmen:   Bart Barlogie, MD, PhD Myeloma Institute for Research and Therapy The University of Arkansas for Medical Sciences Little Rock, Arkansas Elias J. Anaissie, MD Myeloma Institute for Research and Therapy The University of Arkansas for Medical Sciences Little Rock, Arkansas Scientific Committee:  Brian G.M. Durie, MD Cedars-Sinai Comprehensive Cancer Center Los Angeles, California Nikhil Munshi, MD Harvard Medical School Boston, Massachusetts David G. Roodman, MD, PhD University of Pittsburgh Pittsburgh, Pennsylvania

F A C U L T Y

Elias J. Anaissie, MD Myeloma Institute for Research and Therapy The University of Arkansas for Medical Sciences Little Rock, Arkansas Bart Barlogie, MD, PhD Myeloma Institute for Research and Therapy The University of Arkansas for Medical Sciences Little Rock, Arkansas William I. Bensinger, MD Fred Hutchinson Cancer Research Center University of Washington Seattle, Washington Peter Leif Bergsagel, MD Mayo Clinic Scottsdale, Arizona Arthur R. Bradwell, MD University of Birmingham Birmingham, United Kingdom Raymond L. Comenzo, MD Memorial Sloan-Kettering Cancer Center New York, New York Madhav V. Dhodapkar, MD The Rockefeller University New York, New York Brian G.M. Durie, MD Cedars-Sinai Comprehensive Cancer Center Los Angeles, California Joshua Epstein, DSc Myeloma Institute for Research and Therapy The University of Arkansas for Medical Sciences Little Rock, Arkansas Michele Fox, MD Myeloma Institute for Research and Therapy The University of Arkansas for Medical Sciences Little Rock, Arkansas Philip R. Greipp, MD Mayo Clinic Rochester, Minnesota Mohamad Hussein, MD Cleveland Clinic Taussig Cancer Center Cleveland, Ohio Norman Latov, MD, PhD Weill Medical College Of Cornell University New York, New York Nikhil Munshi, MD Harvard Medical School Boston, Massachusetts S. Vincent Rajkumar, MD Mayo Clinic Rochester, Minnesota David G. Roodman, MD, PhD University of Pittsburgh Pittsburgh, Pennsylvania John D. Shaughnessy, Jr., PhD Myeloma Institute for Research and Therapy The University of Arkansas for Medical Sciences Little Rock, Arkansas Steven P. Treon, MD, PhD Dana-Farber Cancer Institute Harvard Medical School Boston, Massachusetts Guido Tricot, MD, PhD Myeloma Institute for Research and Therapy The University of Arkansas for Medical Sciences Little Rock, Arkansas Frits Van Rhee, MD, PhD The University of Arkansas for Medical Sciences Little Rock, Arkansas Ivan Van Riet, MD Academic Hospital Free University Brussels Brussels, Belgium Ronald C. Walker, MD The University of Arkansas for Medical Sciences Little Rock, Arkansas Donna M. Weber, MD MD Anderson Cancer Center Houston, Texas Qing Yi, MD, PhD MD Anderson Cancer Center Houston, Texas Maurizio Zangari, MD The University of Arkansas for Medical Sciences Little Rock, Arkansas

S C I E N T I F I C   T O P I C S

Friday, January 21, 2005 9:00 am Welcome     Session I: Pathogenesis of myeloma 9:05 am Molecular pathogenesis: Genetic heterogeneity and gene expression and resistance John D. Shaughnessy, Jr., PhD 9:30 am Cytogenetics and myeloma Peter Leif Bergsagel, MD 9:55 am Myeloma micro-environment: From disease development to progression and resistance Joshua Epstein, DSc 10:20 am CD 45 and the myeloma stem-cell Speaker Invited 10:45 am Break 11:00 am Homing of myeloma cells to the bone marrow Ivan Van Riet, MD 11:25 am Bone involvement in myeloma David G. Roodman, MD, PhD 11:50 am Lunch     Session II: Diagnosis, staging, and monitoring response of myeloma 1:05 pm International myeloma staging: An update Brian G.M. Durie, MD 1:30 pm FDG-PET scanning in staging and response evaluation Ronald C. Walker, MD 1:55 pm Free light chains and their role in managing myeloma Arthur R. Bradwell, MD     Session III: Supportive care part I 2:20 pm Erasing pain Speaker Invited 2:45 pm Managing anemia and fatigue Speaker Invited 3:10 pm Neuropathies in multiple myeloma and amyloidosis Norman Latov, MD, PhD     Session IV: How I treat multiple myeloma: Expert roundtable 3:35 pm The management of MGUS, smoldering myeloma, solitary plasmacytoma, and refractory and relapsing myeloma Discussion leader: Speaker Invited 5:35 pm Adjourn     Saturday, January 22, 2005     Session V: Supportive care part II 8:00 am Reducing the risk of high dose therapy: Newer tools and better math Elias J. Anaissie, MD 8:25 am Bisphosphonates, bone disease and micro-environment Speaker Invited 8:50 am Mobilization strategies in the difficult to mobilize patient (including AMD) Michele Fox, MD 9:15 am Preventing thrombosis: Point-counterpoint Point: Low-molecular weight heparin is key to prevention Maurizio Zangari, MD Counterpoint: Aspirin is all you need Mohamad Hussein, MD 10:05 am Break     Session VI: Treatment update part I 10:20 am Autologous transplantation: A review of the evidence Guido Tricot, MD, PhD 10:50 am Allogeneic transplantation for high risk myeloma: Point-counterpoint Point: Reduced intensity conditioning is safe and effective therapy Speaker Invited Counterpoint: Time to revisit conventional myeloablative conditioning William I. Bensinger, MD 11:40 am Lunch     Session VII: Treatment update part II 1:00 pm Immunosurveillance and immunotherapy: Ready for prime time? Roundtable discussion Participants: Madhav V. Dhodapkar, MD, Nikhil Munshi, MD, Frits Van Rhee, MD, PhD and Qing Yi, MD, PhD 1:25 pm Thalidomide Donna M. Weber, MD 1:50 pm Thalidomide derived immunomodulatory drugs Speaker Invited 2:15 pm Bortezomib Speaker Invited 2:40 pm Bortezomib plus thalidomide and dexamethasone S. Vincent Rajkumar, MD 3:05 pm Arsenic trioxide, liposomal doxorubicin Speaker Invited 3:30 pm Combination therapies: The total therapy approach Bart Barlogie, MD, PhD 3:55 pm Break     Session VIII: Other plasma cell disorders 4:10 pm Amyloidosis: New insights and treatment including autologous stem cell transplant Raymond L. Comenzo, MD 4:35 pm POEMS: Disease characteristics and management: The Mayo Clinic experience Philip R. Greipp, MD 5:00 pm Waldenstrom’s macroglobulinemia Steven P. Treon, MD, PhD 5:25 pm Adjourn

C O N T I N U I N G  M E D I C A L  E D U C A T I O N

Imedex®, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Imedex, Inc. designates this educational activity for a maximum of 14.5 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the activity.

W H O   S H O U L D   A T T E N D ?

This educational program is intended for hematologists/oncologists and other health care providers who are involved in and/or interested in multiple myeloma or plasma cell disorders. No specific knowledge or skills other than a basic training or familiarity with the practice of hematology/oncology is required for successful participation in this program. Click here to register for this program

O B J E C T I V E S

After successful completion of this program participants should be able to: Describe current treatment options for patients with multiple myeloma and other plasma cell disorders Comment on supportive therapies for patients with myeloma Comment on the prognostic value of cytogenetic markers Discuss immunomodulatory therapies in the treatment of multiple myeloma Evaluate promising new therapeutic strategies for the treatment of multiple myeloma Summarize the key features of the biology of multiple myeloma and other plasma cell disorders

C A L L  F O R   A B S T R A C T S

Participants interested in presenting data should submit abstracts online by December 3, 2004. Abstracts are subject to acceptance by the Scientific Committee. Once accepted, abstracts will be published in the final program book and scheduled for a poster presentation. Acceptance notifications and guidelines for poster presentation will be sent on December 17, 2004. Authors of accepted abstracts who have not registered will have until January 14, 2005 to do so at the discounted rate. After this date, abstracts without registered presenters will be disregarded. Submission Deadline: December 3, 2004 Submission Instructions: Go to www.imedex.com and click “submit an abstract” Follow the online instructions Abstracts must be written in English Accepted format: Word documents, 9 point Arial font, 500 word count limit Use a concise title List affiliations of author(s) as briefly as possible, with city, state and country Use standard and well-accepted abbreviations When using references, use standard and well-accepted formats Abstract content should be single-spaced, typed in lower case and contain: Purpose of the study Summarized description of the project Results and conclusions

R E G I S T R A T I O N

Click here to register for this program Registration Fees Discounted . . . . . . . . . $ 195 (If received by December 10, 2004) Regular . . . . . . . . . . . .$ 295 (If received by January 14, 2005) Full . . . . . . . . . . . . . . .$ 395 (If received after January 14, 2005) Group Discount . . . . . . .– $ 50 (Physician registrants only) Nurses, Fellows , Students* . . . $ 99 (*proof of eligibility must accompany registration) To Register: You may register online at www.imedex.com or call Imedex at +1 (770) 751 7332 or return the registration form in this program by mail or fax. Registration confirmations will be issued before the meeting. To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified. Registration Fee Inclusions: Registration fees include admittance to scientific sessions, conference materials and all functions as specified in the program. Group Discounts: Multiple registrants from the same institute or practice each receive a $50 discount off the published registration fees, provided all registration forms and payments are received together. Only one discount will apply per physician. Discounts do not apply to nurses, fellows and students. Payment: Registration fees and hotel reservation guarantees can be remitted by credit card, check or wire transfer. Checks should be payable to Imedex. To pay via wire transfer, you must add $25 to the registration fee to cover bank charges. Include the full name of the attendee and the name of the conference: 210 Plasma Cell. Attendee is not registered until full payment is received. Wire to: Bank of America, Atlanta, GA, ABA: 0260-0959-3, Account Info: Imedex, Inc., Account: 0000.0106.3308. If the wire originates outside the United States, please add this additional information: Clearing Bank: Bank of America, New York, Swift Code: BOFAUS3N, Clearing Account: 6550305831. Cancellation: For registration fees to be refunded, written notice of cancellation must be received at Imedex by January 14, 2005. The amount of registration fees remitted, minus a $75 administrative charge, will be refunded after the conference. Substitutions are accepted with written notification. Attendees registered at the Nurses, Fellows and Students rate will not receive a refund. After January 14, 2005, no refunds will be made. For hotel deposits to be refunded, written notice of cancellation must be received at Imedex no later than 5 business days prior to your scheduled arrival date. All refunds will be processed after the conference.

H O T E L   A C C O M M O D A T I O N S

The Westin Casuarina 160 East Flamingo Rd. Las Vegas, Nevada 89109 Tel.: +1 (702) 836 9775 Fax: +1 (702) 836 9776 For the convenience of attendees, a limited number of rooms has been reserved at a rate of $179.00 for single or double occupancy, plus tax, currently at 9%. This rate is not guaranteed outside the conference dates. The Westin Casuarina is conveniently located just steps away from the famous Las Vegas "Strip", three miles from the McCarran Airport and one mile from the Las Vegas Convention Center.

O R G A N I Z E R

70 Technology Drive           Alpharetta, GA 30005-3969 USA           Tel.: +1 (770) 751 7332           Fax: +1 (770) 751 7334           Email: meetings@imedex.com           Web: www.imedex.com

© 2004 Imedex®, Inc.